Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity.

Sandra Llorente-PelayoPablo DocioSilvia ArriolaBernardo Alio Lavin-Gomez Maria Teresa García Unzueta María Ángeles Ballesteros María J Cabero-Pérez Domingo González-Lamuño

Published in: BMC pediatrics (2024)

MBDP remains a significant concern in extremely premature newborns. Current diagnostic methods rely on limited biochemical markers. Early detection of low FGF23 levels enables timely interventions, potentially averting demineralization.

Keyphrases

low birth weight
preterm infants
bone mineral density
pregnant women
physical activity
gestational age
bone loss
bone regeneration
postmenopausal women